Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury

Cardiovascular Research

Volumn 76, Issue 3, 2007, Pages 473-481

  Zhao, Ting C ^a   Cheng, Guangmao ^b   Zhang, Ling X ^c   Tseng, Yi T ^a   Padbury, James F ^a  

^a WOMEN AND INFANTS HOSPITAL   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

Author keywords

Histone deacetylase; Ischemia; Signal transduction; Trichostatin A

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE INHIBITOR; LYSINE; SODIUM CHLORIDE; SYNAPTOPHYSIN; TRICHOSTATIN A;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONOTHERAPY; CONTROLLED STUDY; CONVALESCENCE; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART MUSCLE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PERFUSION; HEART PROTECTION; HEART VENTRICLE FUNCTION; IMMUNOFLUORESCENCE; ISCHEMIC PRECONDITIONING; ISOLATED HEART; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; THERAPY DELAY; WESTERN BLOTTING;

ANIMALS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; IMIDAZOLES; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MICE; MICE, INBRED ICR; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; SIGNAL TRANSDUCTION; VENTRICULAR FUNCTION, LEFT;

EID: 35548942629     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2007.08.010     Document Type: Article

References (48)

1. Cheung P., Allis C.D., and Sassone-Corsi P. Signaling to chromatin through histone modifications. Cell 103 (2000) 263-267
2. Hansen J.C., Tse C., and Wolffe A.P. Structure and function of the core histone N-termini: more than meets the eye. Biochemistry 37 (1998) 17637-17641
3. Strahl B.D., and Allis C.D. The language of covalent histone modifications. Nature 403 (2000) 41-45
4. Turner B.M. Histone acetylation and an epigenetic code. BioEssays 22 (2000) 836-845
5. Yuan Z.L., Guan Y.J., Chatterjee D., and Chin Y.E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307 (2005) 269-273
6. Kaiser C., and James S.R. Acetylation of insulin receptor substrate-1 is permissive for tyrosine phosphorylation. BMC Biol 2 (2004) 23
7. Chen L.F., Fischle W., Verdin E., and Greene W.C. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293 (2001) 1653-1657
8. Vigushi D.M., and Coombes R.C. Targeted histone deacetylase inhibition for cancer therapy. Curr Cancer Target 4 (2004) 205-218
9. Hassig C.A., Tong J.K., Fleischer T.C., Owa T., Grable P.G., Ayer D.E., et al. Role for histone deacetylase activity in HDAC1-mediated transcriptional repression. Proc Natl Acad Sci U S A 95 (1998) 3519-3524
10. Taunton J., Hassig C.A., and Schreiber S.L. Mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272 (1996) 408-411
11. Zhang C.L., McKinsey T.A., Chang S., Antos C.L., Hill J.A., and Olson E.N. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110 4 (2002) 479-488
12. Wang A.H., Bertos N.R., Vezmar M., Pelletier N., Crosato M., Heng H.H., et al. HDAC4, A human histone deacetylase related to yeast HDA1, is a transcriptional corepressor. Mol Cell Biol 19 (1999) 7816-7827
13. Johnstone Ricky W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1 (2002) 287-299
14. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1 (2001) 194-202
15. Ren M., Leng Y., Jeong M., Leeds P.R., and Chuang D.M. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem 89 (2004) 1358-1367
16. Antos C.L., McKinsey T.A., Dreitz M., Hollingsworth L.M., Zhang C.L., Schreiber K., et al. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem 278 (2003) 28930-28937
17. Kee H.J., Sohn I.S., Nam K.I., Park J.E., Yin Z., Ahn Y., et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 113 (2006) 51-59
18. Kong Y., Tannous P., Lu G., Berenji K., Rothermel B.A., Olson E.N., et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 113 (2006) 2579-2588
19. Zhao T.C., Taher M.M., Valerie K.C., and Kukreja R.C. p38 Triggers late preconditioning elicited by anisomycin in heart: involvement of NF-kappaB and iNOS. Circ Res 89 (2001) 915-922
20. Stein A.B., Tang X.L., Guo Y., Xuan Y.T., Dawn B., and Bolli R. Delayed adaptation of the heart to stress: late preconditioning. Stroke 35 (2004) 2676-2679
21. Yellon D.M., and Downey J.M. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 83 (2003) 1113-1151
22. Martindale J.J., Wall J.A., Martinez-Longoria D.M., Aryal P., Rockman H.A., Guo Y., et al. Overexpression of mitogen-activated protein kinase kinase 6 in the heart improves functional recovery from ischemia in vitro and protects against myocardial infarction in vivo. J Biol Chem 280 (2005) 669-676
23. Peart J.N., Gross E.R., Headrick J.P., and Gross G.J. Impaired p38 MAPK/HSP27 signaling underlies aging-related failure in opioid-mediated cardioprotection. J Mol Cell Cardiol 42 (2007) 972-980
24. Dana A., Skarli M., Papakrivopoulou J., and Yellon D.M. Adenosine A(1) receptor induced delayed preconditioning in rabbits: induction of p38 mitogen-activated protein kinase activation and Hsp27 phosphorylation via a tyrosine kinase- and protein kinase C-dependent mechanism. Circ Res 86 (2000) 989-997
25. Schulz R., Belosjorow S., Gres P., Jansen J., Michel M.C., and Heusch G. p38 MAP kinase is a mediator of ischemic preconditioning in pigs. Cardiovasc Res 55 (2002) 690-700
26. Haq S.E., Clerk A., and Sugden P.H. Activation of mitogen-activated protein kinases (p38-MAPKs, SAPKs/JNKs and ERKs) by adenosine in the perfused rat heart. FEBS Lett 434 (1998) 305-308
27. Johnson J., Hunter R., McElveen R., Qian X.H., Baliga B.S., and Pace B.S. Fetal hemoglobin induction by the histone deacetylase inhibitor, scriptaid. Cell Mol Biol 51 (2005) 229-238
28. Bugge E., and Ytrehus K. Bradykinin protects against infarction but does not mediate ischemic preconditioning in the isolated rat heart. J Mol Cell Cardiol 28 (1996) 2333-2341
29. Neely J.R., and Grotyohann L.W. Role of glycolytic products in damage to ischemic myocardium. Dissociation of adenosine triphosphate levels and recovery of function of reperfused ischemic hearts. Circ Res 55 (1984) 816-824
30. Sumeray M.S., and Yellon D.M. Ischaemic preconditioning reduces infarct size following global ischaemia in the murine myocardium. Basic Res Cardiol 93 (1998) 384-390
31. Schaper W., Binz K., Sass S., and Winkler B. Influence of collateral blood flow and of variations in MVO2 on tissue-ATP content in ischemic and infarcted myocardium. J Mol Cell Cardiol 19 (1987) 19-37
32. Kabir A.M., Cao X., Gorog D.A., Tanno M., Bassi R., Bellahcene M., et al. Antimycin A induced cardioprotection is dependent on pre-ischemic p38-MAPK activation but independent of MKK3. J Mol Cell Cardiol 39 (2005) 709-717
33. Yoshida M., Kijima M., Akita M., and Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265 (1990) 17174-17179
34. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401 (1999) 188-193
35. Jneid H., Chandra M., Alshaher M., Hornung C.A., Tang X.L., Leesar M., et al. Delayed preconditioning-mimetic actions of nitroglycerin in patients undergoing exercise tolerance tests. Circulation 111 (2005) 2565-2571
36. Chang S., McKinsey T.A., Zhang C.L., Richardson J.A., Hill J.A., and Olson E.N. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol 24 (2004) 8467-8476
37. Trivedi C.M., Luo Y., Yin Z., Zhang M., Zhu W., Wang T., et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3beta activity. Nat Med 13 (2007) 324-331
38. Wang Y., Huang S., Sah V.P., Ross Jr. J., Brown J.H., Han J., et al. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 273 (1998) 2161-2168
39. Cross H.R., Murphy E., Zheng M., Wang Y., and Steenbergen C. Effect of attenuation of p38α and p38β on myocardial contractility and ischemic injury. Circulation 104 (2001) II-101 (abstract)
40. Martin J.L., Avkiran M., Quinlan R.A., Cohen P., and Marber M.S. Antiischemic effects of SB203580 are mediated through the inhibition of p38alpha mitogen-activated protein kinase: Evidence from ectopic expression of an inhibition-resistant kinase. Circ Res 89 (2001) 750-752
41. Sun H.Y., Wang N.P., Halkos M., Kerendi F., Kin H., Guyton R.A., et al. Postconditioning attenuates cardiomyocyte apoptosis via inhibition of JNK and p38 mitogen-activated protein kinase signaling pathways. Apoptosis 11 (2006) 1583-1593
42. Ma X.L., Kumar S., Louden C.S., Lopez B.L., Christoper T.A., Wang C., et al. Inhibition of p38 mitogen-activated protein kinase decrease cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation 99 (1999) 1685-1691
43. Kaiser R.A., Bueno O.F., Lips D.J., Doevendans P.A., Jones F., Kimball T.F., et al. Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo. J Biol Chem 279 (2004) 15524-15530
44. Otsu K., Yamashita N., Nishida K., Hirotani S., Yamaguchi O., Watanabe T., et al. Disruption of a single copy of the p38alpha MAP kinase gene leads to cardioprotection against ischemia-reperfusion. Biochem Biophys Res Commun 302 (2003) 56-60
45. Ping P., and Murphy E. Role of p38 mitogen-activated protein kinases in preconditioning: a detrimental factor or a protective kinase?. Circ Res 86 (2000) 921-922
46. Steenbergen C. The role of p38 mitogen-activated protein kinase in myocardial ischemia/reperfusion injury; relationship to ischemic preconditioning. Basic Res Cardiol 97 (2002) 276-285
47. Sugden P.H., and Clerk A. "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res 83 (1998) 345-352
48. Chen H., Lin R.J., Xie W., Wilpitz D., and Evans R.M. Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell 98 (1999) 675-686